Similar articles

• Cardiac dysfunction in the trastuzumab clinical trials experience.

  Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ, Keefe D. Seidman A, et al. J Clin Oncol. 2002 Mar 1;20(5):1215-21. doi: 10.1200/JCO.2002.20.5.1215. J Clin Oncol. 2002. PMID: 11870163 Clinical Trial.
• Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study.

  Cortes J, Di Cosimo S, Climent MA, Cortés-Funes H, Lluch A, Gascón P, Mayordomo JI, Gil M, Benavides M, Cirera L, Ojeda B, Rodríguez CA, Trigo JM, Vazquez J, Regueiro P, Dorado JF, Baselga J; Spanish Breast Cancer Cooperative Group SOLTI. Cortes J, et al. Clin Cancer Res. 2009 Jan 1;15(1):307-14. doi: 10.1158/1078-0432.CCR-08-1113. Clin Cancer Res. 2009. PMID: 19118059 Clinical Trial.
• 4-years results of weekly trastuzumab and paclitaxel in the treatment of women with HER2/neu overexpressing advanced breast cancer: single institution prospective study.

  Janku F, Pribylova O, Zimovjanova M, Pazdrova G, Safanda M, Zemanova M, Petruzelka L. Janku F, et al. Bull Cancer. 2004 Oct 1;91(10):E279-83. Print 2004 Oct. Bull Cancer. 2004. PMID: 15582895 Clinical Trial.
• Trastuzumab cardiotoxicity: Speculations regarding pathophysiology and targets for further study.

  Schneider JW, Chang AY, Garratt A. Schneider JW, et al. Semin Oncol. 2002 Jun;29(3 Suppl 11):22-8. doi: 10.1053/sonc.2002.34051. Semin Oncol. 2002. PMID: 12138394 Review.
• [Paclitaxel for treatment of advanced breast cancers].

  Ito Y. Ito Y. Nihon Rinsho. 2000 Apr;58 Suppl:259-64. Nihon Rinsho. 2000. PMID: 11026004 Review. Japanese. No abstract available.